PLURI'S MAIT CELLS
Pluri’s placental allogeneic Mucosal- Associated Invariant T (MAIT) cells platform facilitates the development of unconventional immune T cells aiming for immunotherapy of solid tumors.
CAR-T immunotherapy has shown monumental success in treating hematological malignancies, with the FDA approving six autologous CAR-T cell therapies to date. Despite revolutionary progress in hematological malignancies, equivalent success has yet to be duplicated in solid tumor malignancies which present unique challenges.
Offering substantial benefits compared to conventional T cells, Pluri’s MAIT cells are isolated from human placentas, a source rich in highly potent allogeneic immune cells which is often overlooked in traditional therapies. These cells express high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease (GvHD) – a significant advantage over other potential allogeneic products – but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy.
Additionally, Pluri has overcome a key challenge in immunotherapy production using its 3D cell expansion technology. With a rich IP portfolio of 250 global patents in modular bioreactors and 3D manufacturing of placenta-based cells, Pluri has developed a manufacturing process that:
Identifying an ideal target antigen, Chimeric Antigen Receptor (CAR), for the solid tumor is only one part of the challenge. A unique immune cell is needed to overcome conventional T cells disadvantages and successfully reach the desired site and infiltrate the tumor. Pluri’s MAIT cells enable the CAR to reach the tumor, potentially leading to better infiltration and efficacy.
Let’s Work Together
Contact us today to explore a partnership tailored to your current and future clinical drug product manufacturing needs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.